- Home
- MTR vs NERV Comparison
MTR vs NERV Comparison
Compare MTR & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- NERV
- Stock Information
- Founded
- MTR 1979
- NERV 2007
- Country
- MTR United States
- NERV United States
- Employees
- MTR N/A
- NERV N/A
- Industry
- MTR Oil & Gas Production
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- NERV Health Care
- Exchange
- MTR Nasdaq
- NERV Nasdaq
- Market Cap
- MTR 11.7M
- NERV 10.3M
- IPO Year
- MTR N/A
- NERV 2014
- Fundamental
- Price
- MTR $5.23
- NERV $1.78
- Analyst Decision
- MTR
- NERV Hold
- Analyst Count
- MTR 0
- NERV 1
- Target Price
- MTR N/A
- NERV $5.00
- AVG Volume (30 Days)
- MTR 6.9K
- NERV 18.1K
- Earning Date
- MTR 01-01-0001
- NERV 05-05-2025
- Dividend Yield
- MTR 3.60%
- NERV N/A
- EPS Growth
- MTR N/A
- NERV N/A
- EPS
- MTR 0.25
- NERV 0.19
- Revenue
- MTR $731,355.00
- NERV N/A
- Revenue This Year
- MTR N/A
- NERV N/A
- Revenue Next Year
- MTR N/A
- NERV N/A
- P/E Ratio
- MTR $21.74
- NERV $9.00
- Revenue Growth
- MTR N/A
- NERV N/A
- 52 Week Low
- MTR $4.84
- NERV $1.15
- 52 Week High
- MTR $10.32
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- MTR 37.14
- NERV 59.64
- Support Level
- MTR $5.17
- NERV $1.52
- Resistance Level
- MTR $5.52
- NERV $1.81
- Average True Range (ATR)
- MTR 0.25
- NERV 0.17
- MACD
- MTR 0.00
- NERV 0.04
- Stochastic Oscillator
- MTR 30.23
- NERV 95.45
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.